Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 69-77

  Ghanem, Hady ^a   Tank, Niki ^a   Tabbara, Imad A ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFQ1 PROTEIN; ANTINEOPLASTIC AGENT; BRAIN AND ACUTE LEUKEMIA CYTOPLASMIC PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CD34 ANTIGEN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; ECOTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; FMS RELATED TYROSINE KINASE 3 INTERNAL TANDEM DUPLICATION; FMS RELATED TYROSINE KINASE 3 TYROSINE KINASE DOMAIN; ISOCITRATE DEHYDROGENASE; LACTATE DEHYDROGENASE; LESTAURTINIB; MENINGIOMA 1 PROTEIN; MIDOSTAURIN; MIXED LINEAGE LEUKEMIA PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NUCLEOPHOSMIN; PROTEIN; PROTEIN TYROSINE KINASE; QUIZARTINIB; RAS PROTEIN; RETINOIC ACID; SORAFENIB; SUNITINIB; TEN ELEVEN TRANSLOCATION 2 PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE NONPROMYELOCYTIC LEUKEMIA; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CYTOGENETICS; DNA METHYLATION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DUPLICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LEUKOCYTE COUNT; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; ONCOGENE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NEOPLASM, RESIDUAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84155165116     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22197     Document Type: Review

References (150)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.
2. Kebriaei P, de Lima M, Estey E. Management of Acute Leukemias. DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology, Vol. 2. New York: Lippincott Williams & Wilkins; 2008. pp 2232-2265.
3. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136.
4. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
5. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
6. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
7. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
8. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
9. Dohner Hartmut. Implications of the Molecular Characterization of Acute Myeloid Leukemia. Hematology 2004; 412-419.
10. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005; 106: 3740-3746.
11. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-3739.
12. Mrozek K, Dohner H, Bloomfield CD. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: Recent advances. Curr Opin Hematol 2007; 14: 106-114.
13. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011-4020.
14. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854-2861.
15. Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624-633.
16. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic Significance of Gene and MicroRNA Expression Signatures Associated With CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. J Clin Oncol 2008; 26: 5078-5087.
17. Gaidzik V, Döhner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008; 35: 346-355.
18. Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A. Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet 1984; 11: 332-350.
19. Arthur DC, Berger R, Golomb HM, et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 1989; 40: 203-216.
20. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
21. Schlenk RF, Dohner K, Krauter J, et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med 2008; 358: 1909-1918.
22. Wouters BJ, Alberich Jordà M, Keeshan K, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007; 110: 3706-3714.
23. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 9234-9242.
24. Rucker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006; 24: 3887-3894.
25. Ley TJ, Minx PJ, Walter MJ, et al. A pilot study of highthroughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci U S A 2003; 100: 14275-14280.
26. Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Hematologica 2007; 92: 519-532.
27. Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer. Nat Rev 2006; 6: 493-505.
28. Falini B, Mecucci C, Tiacci E, et al. Gimema Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352; 254-266.
29. Schlenk RF, Dohner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia: Results from AMLSG Trial AML HD98B. Haematologica 2009; 94: 54-60.
30. Chen WG, Rassidakis GZ, Medeiros LJ. Nucleophosmin gene mutations in acute myeloid leukemia. Arch Pathol Lab Med 2006; 130: 1687-1692.
31. Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): Biological and clinical features. Blood 2007; 109: 874-885.
32. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-3739.
33. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011-4020.
34. Becker H, Marcucci G, Maharry K, et al. Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. J Clin Oncol 2010; 596-604.
35. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776.
36. Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010; 115: 3776-3786.
37. Rollig C, Thiede C, Gramatzki M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia-results of 909 patients entered into the prospective AML96 trial. Blood 2006; 116: 971-978.
38. Liu H, Tan BC, Tseng KH, et al. Nucleophosmin acts as a novel AP2 alphabinding transcriptional corepressor during cell differentiation. EMBO Rep 2007; 8: 394-400.
39. Schlenk RF, Frohling S, Hartmann F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2008; 18: 1798-1803.
40. Schlenk RF, Dohner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia: Results from AMLSG Trial AML HD98B. Haematologica 2009; 94: 54-60.
41. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 2001; 61: 7233-7239.
42. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
43. Kiyoi H, Naoe T. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol 2006; 83: 301-308.
44. Fathi AT, Chabner BA. FLT3 Inhibition as Therapy in Acute Myeloid Leukemia: A Record of Trials and Tribulations. Oncologist 2011; 16: 1162-1174.
45. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-665.
46. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
47. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002; 100: 4372-4380.
48. Kainz B, Heintel D, Marculescu R, et al. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J 2002; 3: 283-289.
49. Ciolli S, Vannucchi AM, Leoni F, et al. Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia. Leuk Lymphoma 2004; 45: 73-78.
50. Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11: 1416-1424.
51. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103: 1901-1908.
52. Kayser S, Schlenk R, Correa Londono M, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009; 114: 12.
53. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): An analysis of 1135 patients, excluding acute prolyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005; 106: 3658-3665.
54. Harshabad Singh, Lillian L.Werner, Salma Asali, et al. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol 2011; 86: 625-627.
55. Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia 2005; 19: 1345-1349.
56. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110: 1262-1270.
57. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (CEBPalpha), in acute myeloid leukemia. Nat Genet 2001; 3: 263-270.
58. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 2003; 4: 31-40.
59. Wouters B, Löwenberg B, Erpelinck-Verschueren C, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088-3091.
60. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117: 2469-2475.
61. Green C, Koo K, Hills R, et al. Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations. J Clin Oncol 2010; 28: 2739-2747.
62. Lu Y, Chen W, Chen W, et al. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics. Am J Hematol 2010; 85: 426-430.
63. Whitman SP, Ruppert AS, Marcucci G, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study. Blood 2007; 109: 5164-5167.
64. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961-2968.
65. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997; 9: 209-225.
66. Little SE, Hanks SP, King-Underwood L, et al. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: A UK Children's Cancer Study Group Study. J Clin Oncol 2004; 22: 4140-4146.
67. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007; 9: 1-17.
68. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3: 179-198.
69. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429-5435.
70. Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 2008; 26: 4595-4602.
71. Hou H, Huang T, Lin L, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010; 115: 5222-5231.
72. Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2011; 28: 578-585.
73. Bacher U, Haferlach T, Schoch C, et al. Implication of NRAS mutations in AML: A study of 2502 patients. Blood 2006; 107: 3847-3853.
74. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence out-come in patients younger than 60 years. Blood 2005; 106: 2113-2119.
75. Neubauer A, Maharry K, Mrozek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study. J Clin Oncol 2008; 26: 4603-4609.
76. Lee SH, Jo SH, Lee SM, et al. Role of NADP-- dependent isocitrate dehydrogenase (NADP--ICDH) on cellular defence against oxidative injury by gammarays. Int J Radiat Biol 2004; 80: 635-642.
77. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
78. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biological characteristics in adult acute myeloid leukemia bearing isocitrate dehydrogenase 1 (IDH1) mutation. Blood 2010; 115: 2749-2754.
79. Wagner K, Damm F, Göhring G, et al. Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. J Clin Oncol 2010; 28: 2356-2364.
80. Ho PA, Alonzo TA, Kopecky KJ, et al. Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010; 24: 909-913.
81. Schnittger S, Haferlach C, Ulke M, et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010; 116: 5486-5496.
82. Marcucci G, Maharry K, Wu Y, et al. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 2010; 28: 2348-2355.
83. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: A study by the Acute Leukemia French Association group. J Clin Oncol 2010; 28: 3717-3723.
84. Paschka P, Schlenk R, Gaidzik V, et al. IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication. J Clin Oncol 2010; 28: 3636-3643.
85. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood 2010; 116: 2122-2126.
86. Green CL, Evans CM, Hills RK, et al. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010; 116: 2779-2782.
87. Chou WC, Lei WC, Ko BS, et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011; 25: 246-253.
88. Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010; 116: 614-616.
89. Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations depends on the location of the mutation. Blood 2011; 118: 409-412.
90. Lugthart S, Figueroa ME, Bindels E, et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 2011; 117: 234-241.
91. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
92. Ley T, Ding L, Walter M, et al. DNMT3A Mutations in Acute Myeloid Leukemia. N Engl J Med 2010; 363: 2424-2433.
93. Thol F, Damm F, Lüdeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29: 2889-2896.
94. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343-1345.
95. Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010; 116: 1132-1135.
96. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 2011; 29: 1373-1381.
97. Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011 Aug 9. [Epub ahead of print].
98. Baldus CD, Tanner SM, Kusewitt DF, et al. BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol 2003; 31: 1051-1056.
99. Baldus CD, Thiede C, Soucek S, et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: Prognostic implications. J Clin Oncol 2006; 24: 790-797.
100. Baldus CD, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study. Blood 2003; 102: 1613-1618.
101. Beinz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11: 1416-1424.
102. Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 2008; 111: 5371-5379.
103. Schwind S, Marcucci G, Maharry K, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA-expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 2011; 116: 5660-5669.
104. Santamaría C, Chillón MC, García-Sanz R, et al. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol 2010; 89: 453-458.
105. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146-151.
106. Papas TS, Watson DK, Sacchi N, et al. ETS family of genes in leukemia and Down syndrome. Am J Med Genet Suppl 1990; 7: 251-261.
107. Rainis L, Toki T, Pimanda JE, et al. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res 2005; 65: 7596-7602.
108. Marcucci G, Maharry K, Whitman P, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2007; 25: 3337-3343.
109. Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: A comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 2009; 27: 5031-5038.
110. Van Wely KHM, Molijn AC, Buijs A, et al. The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene 2003; 22: 699-709.
111. Sutton ALM, Zhang X, Ellison TI, et al. The 1, 25(OH)2D3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation. Mol Endocrinol 2005; 19: 2234 - 2244.
112. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006; 108: 3898-3905.
113. Langer C, Marcucci G, Holland KB, et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 2009; 27: 3198-3204.
114. Heuser M, Argiropoulos B, Florian Kuchenbauer F, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 2007; 110: 1639-1647.
115. Tse W, Zhu W, Chen HS, Cohen A. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 1995; 85: 650-656.
116. Tse W, Hu ZB, Geng DJ, et al. AF1q, a fusion partner with MLL, has restricted expression in the normal bone marrow cell hierarchy. Blood 1998; 92: 2437.
117. Tse W, Meshinchi S, Alonzo TA, et al. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 2004; 104: 3058-3063.
118. Tse W, Joachim DH, Stirewalt D, et al. Increased AF1q gene expression in high-risk myelodysplastic syndrome. Br J Haematol 2005; 128: 218-220.
119. Strunk CJ, Platzbecker U, Thiede C, et al. Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics. Am J Hematol 2009; 84: 308-309.
120. Morishita K, Parker DS, Mucenski ML, et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988; 54: 831-840.
121. Buonamici S, Li D, Chi Y, et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 2004; 114: 713-719.
122. Van Waalwijk van Doorn-Khosrovani SB, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 2003; 101: 837-845.
123. Lugthart S, Van Drunen E, Van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: Prevalence of EVI1 over-expression and chromosome 3q26 abnormalities underestimated. Blood 2008; 11: 4329-4337.
124. Santamaria CM, Chillon MC, Garcia-Sanz R, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009; 114: 148-152.
125. Groschel S, Lugthart S, Schlenk RF, et al. High EVEN Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities. J Colin Onslow 2010; 28: 2101-2107.
126. Benezra R, Davis RL, Lockshon D, et al. The protein Id: A negative regulator of helix-loop-helix DNA binding proteins. Cell 1990; 61: 49-59.
127. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2002; 113: 3897-3905.
128. Lin CQ, Singh J, Murata K, et al. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 2000; 60: 1332-1340.
129. Ouyang XS, Wang X, Lee DT, et al. Over expression of ID-1 in prostate cancer. J Urol 2002; 167: 2598-2602.
130. Fong S, Itahana Y, Sumida T, et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 2003; 100: 13543-13548.
131. Schoppmann SF, Schindl M, Bayer G, et al. Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer 2003; 104: 677-682.
132. Tang R, Hirsch P, Fava F, et al. High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. Blood 2009; 114: 2993-3000.
133. Tam WF, Gu TL, Chen J, et al. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 2008; 112: 1981-1992.
134. Al-Mawali A, Gillis D, Lewis I, et al. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2009; 131: 16-26.
135. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521-2528.
136. Krauter J, Gorlich K, Ottmann O, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003; 21: 4413-4422.
137. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220-2231.
138. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011; 29: 2709-2716.
139. Bacher U, Badbaran A, Fehse B, et al. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. J Exp Hematol 2009; 37: 135-142.
140. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative PCR detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: An European LeukemiaNet Study. J Clin Oncol 2009; 27: 5195-5201.
141. Qin Y, Zhu H, Jiang B, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009; 33: 384-390.
142. Scholl S, Loncarevic IF, Krause C, et al. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia. Leuk Res 2005; 29: 849-853.
143. Chou WC, Hou HA, Liu CY, et al. Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. Ann Oncol 2011; 22: 696-704.
144. Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002; 100: 2393-2398.
145. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387-2392.
146. Tiesmeier J, Czwalinna A, Muller-Tidow C, et al. Evidence for allelic evolution of CEBPalpha mutations in acute myeloid leukemia. Br J Haematol 2003; 123: 413-419.
147. Smith LL, Pearce D, Smith ML, et al. Development of quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia. Br J Haematol 2006; 133: 103-105.
148. Kong XT, Ida K, Ichikawa H, et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood 1997; 90: 1192-1199.
149. Rockova V, Abbas S, Wouters BJ, et al. Risk-stratification of intermediate-risk acute myeloid leukemia: Integrative analysis of a multitude of gene mutation and expression markers. Blood 2011; 118: 1069-1076.
150. Damm F, Heuser M, Morgan M, et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 2011; 28;117: 4561-4568.